35779-32-9

Basic information

• Product Name: Methanediamine, 1-(4-methylphenyl)-N,N'-bis[(4-methylphenyl)methylene]-
• CAS NO: 35779-32-9
• Molecular Formula: C24H24N2
• Molecular Weight: 340.468
• Mol File: 35779-32-9.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Methanediamine, 1-(4-methylphenyl)-N,N'-bis[(4-methylphenyl)methylene]-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanediamine, 1-(4-methylphenyl)-N,N'-bis[(4-methylphenyl)methylene]-(35779-32-9)
• EPA Substance Registry System: Methanediamine, 1-(4-methylphenyl)-N,N'-bis[(4-methylphenyl)methylene]-(35779-32-9)

Safety Data

• Hazardous Substances Data: 35779-32-9(Hazardous Substances Data)

Upstream product

• 108-88-3 toluene 
• 102852-88-0 (2R,3R)-2-(4-Methyl-benzyl)-3-phenyl-oxaziridine 
• 104-87-0 4-methyl-benzaldehyde 

Downstream Products

• 51625-68-4 1,3,5-tris(3-nitrophenyl)-2,4-diazapenta-1,4-diene 
• 109253-44-3 3-amino-2-phenyl-3-p-tolyl-propionic acid ethyl ester 
• 77841-40-8 2,4,6,8-tetrakis<4-methylphenyl>-3,7-diazabicyclo<3.3.1>nonan-9-one 
• 1588-49-4 4,4'-dimethylstilbene 
• 98180-43-9 bis(4-methylbenzyl)amine 
• 1224850-72-9 N-(4-methylbenzylideneamino)(4-methylphenyl)methyl-2-(4-methyl-phenyl)-4,5-diphenyl-1,2-dihydro-3H-pyrrol-3-one 
• 1347740-01-5 C₂₄H₃₄NO₃P 
• 1347740-02-6 C₁₈H₂₂NO₃P 
• 871315-36-5 (p-Tolyl-{[1-p-tolyl-meth-(E)-ylidene]-amino}-methyl)-phosphonic acid diethyl ester 
• 1347740-14-0 C₁₆H₂₈NO₃P 
• 1347739-94-9 O,O-dimethyl [2-(4,6-dimethoxypyrimidin-2-yloxy)phenoxyamino](p-tolyl)methylphosphonate 
• 1347739-96-1 O,O-diethyl [2-(4,6-dimethoxypyrimidin-2-yloxy)phenoxyamino](p-tolyl)methylphosphonate 
• 1347739-93-8 O,O-di-n-butyl [2-(4,6-dimethoxypyrimidin-2-yloxy)phenoxyamino](p-tolyl)methylphosphonate 

Relevant articles and documents

Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway

Four series of hypoxia-inducible factor-1 alpha (HIF-1α) functioning derivatives stemming from modifications to the C-29 carboxyl group of celastrol were designed and synthesized, and their anticancer activities were evaluated. To address the structure and activity relationship of each derivative, extensive structural changes were made. HRE luciferase reporter assay demonstrated that 12 modified compounds showed superior HIF-1α inhibitory activity. Among them, compound C6 exhibited the best features: firstly, the strongest HIF-1α inhibitory activity (IC50 = 0.05 μM, 5-fold higher than that of celastrol); secondly, lower cytotoxicity (22-fold lower, C6-16.85 μM vs celastrol-0.76 μM). Thus, the safety factor of C6 was about 112 times higher than that of celastrol. Western blot assay indicated that C6 may inhibit the expression of HIF-1α protein in cells. Additionally, C6 hindered tumor cell cloning, migration and induced cell apoptosis. It is worth mentioning that in the mouse tumor xenograft model, C6 (10 mg/kg) displayed good antitumor activity in vivo, showing a better inhibition rate (74.03%) than the reference compound 5-fluorouracil (inhibition rate, 59.58%). However, the celastrol treatment group experienced collective death after four doses of the drug. Moreover, C6 minimally affected the mouse weight, indicating that its application in vivo has little toxic effect. H&E staining experiments show that it could also exacerbate the degree of tumor cell damage. The results of water solubility experiment show that the solubility of C6 is increased by 1.36 times than that of celastrol. In conclusion, C6 is a promising antitumor agent through HIF-1α pathway.

Design, Synthesis, and in Vitro and in Vivo Biological Evaluation of Limonin Derivatives for Anti-Inflammation Therapy

In this study, limonin derivatives were used to design new anti-inflammatory compounds with high pharmacological activity and low toxicity. A total of 23 new limonin derivatives were discovered, synthesized, and screened for their anti-inflammatory activity against lipopolysaccharide (LPS)-treated RAW 264.7 cells. Of them, compound f4 was found to be the most active, with a higher efficiency compared with limonin and celecoxib. Subsequently, we studied the mechanism underlying the activity of f4 and found that it inhibited proinflammatory cytokines by blocking the NF-κB/MAPK signaling pathway in LPS-treated RAW 264.7 cells as well as mice. In conclusion, f4 may be a promising anti-inflammatory lead compound.

Adducts of Triallylborane with Ammonia and Aliphatic Amines as Stoichiometric Allylating Agents for Aminoallylation Reaction of Carbonyl Compounds

Triallylborane-amines adducts are effective stoichiometric allylating agents in the aminoallylation reaction of carbonyl compounds in methanol. Moreover, copper-catalyzed diastereoselective allylation of Ellman's imine was achieved with triallylborane-methylamine adduct.